Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD.

Neurology - 22 Oct 1999

Oliveri R L, Annesi G, Zappia M, Civitelli D, Montesanti R, Branca D, Nicoletti G, Spadafora P, Pasqua A A, Cittadella R, Andreoli V, Gambardella A, Aguglia U, Quattrone A

Abstract excerpt

OBJECTIVE: To investigate whether polymorphisms in the genes for dopamine receptors D1 and D2 are associated with the risk of developing peak-dose dyskinesias in PD. BACKGROUND: Peak-dose dyskinesias are the most common side effects of levodopa therapy for PD. The identified predictors may only partially account for the risk of developing peak-dose dyskinesias because a substantial proportion of patients never...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiparkinson Agents
Share to Case-Control Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dyskinesia, Drug-Induced

Share to Dyskinesias

Share to Levodopa

Share to Parkinson Disease

Share to Receptors, Dopamine D2

Share to Tandem Repeat Sequences

Source

Identifiers

PMID: 10534246
DOI: 10.1212/wnl.53.7.1425

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD.PMID 10534246Read ↗

Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study.Semantic proximity Read ↗

Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease.Semantic proximity Read ↗

<scp>l</scp>-Dopa-induced adverse effects in PD and dopamine transporter gene polymorphismSemantic proximity Read ↗

The role of genetic factors in the occurrence of levodopa-induced motor complications in Parkinson's disease.Semantic proximity Read ↗

Association between DRD2 and DRD3 gene polymorphisms and gastrointestinal symptoms induced by levodopa therapy in Parkinson's disease.Semantic proximity Read ↗

Polymorphisms of Dopamine Receptor Genes and Risk of L-Dopa-Induced Dyskinesia in Parkinson's Disease.Semantic proximity Read ↗

Polymorphisms of dopamine receptor and transporter genes and Parkinson's disease.Semantic proximity Read ↗

The catechol-O-methyltransferase and monoamine oxidase B polymorphisms and levodopa therapy in the Iranian patients with sporadic Parkinson's disease.Semantic proximity Read ↗

Association of the DRD2 CAn-STR and DRD3 Ser9Gly polymorphisms with Parkinson's disease and response to dopamine agonists.Semantic proximity Read ↗

Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson's disease.Semantic proximity Read ↗

Tryptophan hydroxylase type 2 variants modulate severity and outcome of addictive behaviors in Parkinson's disease.Semantic proximity Read ↗

Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.